Evidence map›Paper›PMID 41868802›Full record

ArticlePeerJ2026

Coagulation factor II receptor-like 1 as a prognostic and immuno-modulatory factor in head and neck squamous cell carcinoma.

Yong Gang Dai, Shiliang Cheng, Wei Wang, Hongya Wang, Lu Zhang, Xuewei Zhuang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yong Gang DaiDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Shandong University, Jinan City, Shandong Province, China.
Shiliang ChengDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Shandong University, Jinan City, Shandong Province, China.
Wei WangDepartment of Clinical Microbiology Laboratory, Shandong Second Provincial General Hospital, Jinan City, Shandong Province, China.
Hongya WangDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Shandong University, Jinan City, Shandong Province, China.
Lu ZhangDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Shandong University, Jinan City, Shandong Province, China.
Xuewei ZhuangDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Shandong University, Jinan City, Shandong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) remains a major cause of cancer mortality, and robust biomarkers are needed for prognosis stratification and immuno-oncology research. We investigated coagulation factor II receptor-like 1 (F2RL1) in HNSCC, focusing on expression, clinical outcomes and immune associations. Methods: RNA sequencing and clinical follow-up data from The Cancer Genome Atlas head and neck squamous cell carcinoma cohort (TCGA-HNSC) were analysed. Three independent Gene Expression Omnibus (GEO) cohorts (GSE9844, GSE55547 and GSE55548) were used for external confirmation, with preprocessing and differential-expression exports generated using Xiantao Academic. Immune infiltration, functional enrichment and multi-omics annotations were assessed. Experimental validation was performed using reverse transcription quantitative polymerase chain reaction (RT-qPCR), western blotting and immunohistochemistry (IHC). Results: F2RL1 was significantly upregulated in HNSCC and was associated with worse overall survival (OS). Expression differences were consistent across the three GEO cohorts. F2RL1 showed significant associations with immune cell infiltration and immune checkpoint genes, and correlated with DNA methylation features and N6-methyladenosine (m6A) regulators. A nomogram was constructed to estimate 1-, 3- and 5-year OS. Conclusion: F2RL1 is reproducibly overexpressed in HNSCC and is linked to adverse outcomes and immune-related features, supporting its potential as a prognostic biomarker and candidate therapeutic target.

Indexed as

Biomarkers, TumorHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisUp-RegulationBiomarkers, TumorF2RL1Head and neck squamous cell carcinomaImmune infiltrationN6-methyladenosinePrognosis

Identifiers

PMID41868802
PMCPMC13005615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.